Prof Stephen Hunger talks to ecancer at the ALL Assembly 2018 Meeting in Amsterdam about the targeted therapies for Philadelphia-like ALL.
Prof Hunger discusses some of the key questions surrounding targeted therapies for Philadelphia-like ALL and how to show it improves outcomes.
He also considers how to treat T-cell ALL and whether or not technological advances will alter the landscape for treatment in the near future.
ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.